Olmesartan Medoxomil/Hydrochlorothiazide Krka (Olmesartan Medoxomil, Hydrochlorothiazide)

Olmesartan medoxil selectively blocks AT1 receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. Hydrochlorothiazide acts on the distal convoluted tubule to inhibit sodium‑chloride reabsorption, increasing urine output and reducing plasma volume. Together they lower systemic vascular resistance and blood pressure.

The prescribed dose is individualized by the treating clinician based on the patient’s blood pressure, renal function, and response to therapy. The prescriber determines the appropriate strength and dosing schedule, which is typically once daily.

The combination is contraindicated in the second and third trimesters of pregnancy because it can harm the fetus. Use in the first trimester requires a careful risk‑benefit assessment. Limited data are available for breastfeeding; the drug may pass into milk, so consultation with a healthcare professional is advised.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Olmesartan Medoxomil/Hydrochlorothiazide offers the advantage of combining an ARB with a thiazide diuretic in a single tablet, simplifying regimens and improving adherence. Compared with ACE‑inhibitor‑diuretic combos, it avoids cough and angio‑edema associated with ACE inhibitors, while providing comparable blood‑pressure reduction.

Store the tablets at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the container tightly closed and out of reach of children.

The medication is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule prescribed by their healthcare provider.

Serious adverse events include severe hypotension, acute kidney injury, hyperkalemia, angio‑edema and significant electrolyte disturbances. Patients should be monitored for signs of these conditions, especially during treatment initiation or dose changes.

The combination should be avoided in patients with known hypersensitivity to olmesartan, hydrochlorothiazide or any excipients, in those with severe renal impairment, hyperkalemia, or in the second and third trimesters of pregnancy. Clinicians should also exercise caution in patients with hepatic disease or a history of angio‑edema.